RxSight(US:RXST) Globenewswire·2025-09-21 10:45Core Viewpoint - Rosen Law Firm is reminding investors who purchased securities of RxSight, Inc. during the specified Class Period of the upcoming lead plaintiff deadline for a class action lawsuit [1][2] Group 1: Class Action Details - The class action lawsuit has been filed against RxSight, Inc. for allegedly misleading statements regarding the company's growth and performance during the Class Period [4] - Investors who purchased RxSight securities may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1][2] - The lead plaintiff must file a motion with the Court by September 22, 2025, to represent other class members in the litigation [2] Group 2: Allegations Against RxSight - The lawsuit claims that RxSight misrepresented the effectiveness of its field organization and the adoption rates of newer customer cohorts, which were actually underperforming [4] - It is alleged that the utilization across the installed base was declining, contradicting the company's claims of rising utilization [4] - As a result of these misleading statements, investors purchased shares at artificially inflated prices, leading to financial damages when the truth was revealed [4] Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including the largest against a Chinese company at the time [3] - The firm has been consistently ranked among the top firms for securities class action settlements and has recovered hundreds of millions of dollars for investors [3] - Founding partner Laurence Rosen has been recognized as a leading figure in the plaintiffs' bar, further establishing the firm's credibility [3]